Head of Global Product Strategy & Commercialization · BIOGEN INC. (BIIB)

Rachid Izzar

FY2023 is the first fiscal year CompBrief holds for Rachid Izzar as a named executive officer of BIOGEN; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$5,447,830

Salary $591,179Stock awards $4,182,544

4th of 5 named executive officers at Biogen by FY2023 total.

5 named officers on file for BIOGEN, FY2023

Rachid Izzar’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • BIIB’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BIOGEN’s whole pay program stands against its peers

  • BIOGEN’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BIIB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Rachid Izzar’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Rachid Izzar compensation by year

BIOGEN Summary Compensation Table · the one fiscal year held
In US dollars, as BIOGEN reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$591,179
Bonus$0
Stock awards$4,182,544
Option awards$0
Non-equity incentive$574,088
Pension and deferred compensation$0
All other$100,019
Total$5,447,830

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOGEN INC. DEF 14A filed April 26, 2024, accession 0001193125-24-118313, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BIOGEN INC. filed document, accession 0001193125-24-118313. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU6,130$1,586,260—
RSU6,130$1,586,260—
PSU4,545$1,176,110—
RSU3,030$784,073—
RSU2,439$631,140—
PSU727$188,126—

Per the Outstanding Equity Awards at Fiscal Year-End table in BIOGEN INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

21 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-13Grant or award derivative—7,390$0.007,390
2026-02-06Exercise or conversion derivative—3,043$0.006,087
2026-02-06Tax withholding—805$201.187,399
2026-02-06Exercise or conversion—2,044$0.008,204
2026-02-06Exercise or conversion—3,043$0.0011,786
2026-02-06Exercise or conversion derivative—1,802$0.001,802
2026-02-06Exercise or conversion—1,802$0.009,201
2026-02-06Tax withholding—458$201.188,743

The 8 most recent of 21 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments BIOGEN discloses, by trigger · FY2023
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$1,734,706$0$38,127$1,804,833
Change in control and involuntary termination$2,081,647$4,699,427$45,752$6,858,826
Retirement$0$0$0$0

Per the Potential Payments Upon Termination or Change in Control table in BIOGEN INC.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.

BIOGEN’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Michael McDonnellExecutive Vice President and Chief Financial Officer$7,167,601
Susan AlexanderExecutive Vice President, Chief Legal Officer$6,703,852
Nicole MurphyHead of Pharmaceutical Operations and Technology$5,714,319
Rachid Izzar · this pageHead of Global Product Strategy & Commercialization$5,447,830
Christopher ViehbacherPresident and Chief Executive Officer$4,069,913

The full BIOGEN compensation record

free company brief

This page is one person within BIOGEN's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the BIOGEN proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOGEN's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rachid Izzar's compensation dossier · One-time report. No refunds.